180 related articles for article (PubMed ID: 34712485)
1. Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: A pilot study.
Jain M; Kamalov D; Tivtikyan A; Balatsky A; Samokhodskaya L; Okhobotov D; Kozlova P; Pisarev E; Zvereva M; Kamalov A
Mol Clin Oncol; 2021 Dec; 15(6):253. PubMed ID: 34712485
[TBL] [Abstract][Full Text] [Related]
2. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
[TBL] [Abstract][Full Text] [Related]
3. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
[TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
5. Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study.
Batista R; Vinagre J; Prazeres H; Sampaio C; Peralta P; Conceição P; Sismeiro A; Leão R; Gomes A; Furriel F; Oliveira C; Torres JN; Eufrásio P; Azinhais P; Almeida F; Gonzalez ER; Bidovanets B; Ecke T; Stinjs P; Pascual ÁS; Abdelmalek R; Villafruela A; Beardo-Villar P; Fidalgo N; Öztürk H; Gonzalez-Enguita C; Monzo J; Lopes T; Álvarez-Maestro M; Servan PP; De La Cruz SMP; Perez MPS; Máximo V; Soares P
Front Genet; 2019; 10():1237. PubMed ID: 31921291
[TBL] [Abstract][Full Text] [Related]
6. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary
Hosen MI; Forey N; Durand G; Voegele C; Bilici S; Avogbe PH; Delhomme TM; Foll M; Manel A; Vian E; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Boureille A; Pisarev E; Salas AROSE; Monteiro-Reis S; Henrique R; Byrnes G; Jeronimo C; Scelo G; McKay JD; Calvez-Kelm FL; Zvereva M
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260905
[TBL] [Abstract][Full Text] [Related]
7. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
Zvereva M; Hosen MI; Forey N; Sheikh M; Kannengiesser C; Ba I; Manel A; Vian E; Le Calvez-Kelm F
Methods Mol Biol; 2023; 2684():213-228. PubMed ID: 37410237
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
9. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
10. Activating Telomerase
Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
[TBL] [Abstract][Full Text] [Related]
11. Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of
Jain M; Tivtikyan A; Kamalov D; Avdonin S; Rakhmatullin T; Pisarev E; Zvereva M; Samokhodskaya L; Kamalov A
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831030
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
[TBL] [Abstract][Full Text] [Related]
13. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
14. [The role of telomerase activity in non-invasive diagnostics of bladder cancer].
Glybochko PV; Alyaev JG; Potoldykova NV; Polyakovsky KA; Vinarov AZ; Glukhov AI; Gordeev SA
Urologiia; 2016 Aug; (4):76-81. PubMed ID: 28247730
[TBL] [Abstract][Full Text] [Related]
15. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
18.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
19. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
Wang K; Liu T; Liu L; Liu J; Liu C; Wang C; Ge N; Ren H; Yan K; Hu S; Björkholm M; Fan Y; Xu D
Oncotarget; 2014 Apr; 5(7):1829-36. PubMed ID: 24742867
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]